Children with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)

Basit Öğe Kaydı
dc.contributor.authorDinleyici, Ener Cagri
dc.contributor.authorKurugol, Zafer
dc.contributor.authorKara, Ates
dc.contributor.authorTezer, Hasan
dc.contributor.authorTas, Mehmet Ali
dc.contributor.authorGuler, Ekrem
dc.contributor.authorYasa, Olcay
dc.date.accessioned2024-04-24T16:18:36Z
dc.date.available2024-04-24T16:18:36Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Varicella in previously immunized individuals, known as breakthrough varicella. While the majority of breakthrough cases are mild, some may be severe, requiring hospitalization in previously healthy children or children with an underlying condition. Methods: This report, as a part of the prospective national pediatric varicella hospitalizations study (including 29 centers, represent 50% of pediatric population) in Turkey, is aimed to evaluate breakthrough varicella infection requiring hospitalization before the routine use of single-dose live varicella vaccine in national program from 2008 to 2013 (<10% of the pediatric age group received a single-dose vaccine). Results: In the time period, 1939 children were hospitalized due to varicella infection in Turkey; 36 children (20 boys, 16 girls, mean age 68.0+37.6 months, all received single dose live varicella vaccine) with breakthrough varicella infection. Breakthrough varicella infection might be severe in previously healthy children (61.1%) and children with immune-compromising conditions (38.9%). The time elapsed between vaccination and hospitalization was approximately 5 years, and neurological complications, mainly encephalitis and meningitis, were the most common reason for hospitalization in previously healthy children. Conclusion: Pediatric breakthrough varicella requiring hospitalization have been seen in Turkey, is mainly observed in previously healthy children at 5 years after a single-dose varicella vaccine. The varicella vaccine has been implemented as part of the National Immunization Program in Turkey in 2013 (a single dose at age 12 months). Further surveillance in the same settings could evaluate the effectiveness of national immunization with single-dose varicella vaccine at 12 months of age and potential need for second dose of vaccine. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.vaccine.2015.06.029
dc.identifier.endpage3987en_US
dc.identifier.issn0264-410X
dc.identifier.issn1873-2518
dc.identifier.issue32en_US
dc.identifier.pmid26133048
dc.identifier.scopus2-s2.0-84937525441
dc.identifier.scopusqualityQ1
dc.identifier.startpage3983en_US
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2015.06.029
dc.identifier.urihttps://hdl.handle.net/11468/16193
dc.identifier.volume33en_US
dc.identifier.wosWOS:000358460500031
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofVaccine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectVaricellaen_US
dc.subjectChickenpoxen_US
dc.subjectVaricella Vaccineen_US
dc.subjectBreakthrough Varicellaen_US
dc.titleChildren with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)en_US
dc.titleChildren with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu